

A meager supply from the bone marrow: Macrophages in tissues (mostly) renew themselves

Most cells in the blood arise from stem cells in the bone marrow. Exceptions are macrophages, a type of phagocytic cell that forms part of the immune system. In a collaboration between the German Cancer Research Center in Heidelberg and King's College in London, scientists have discovered that most macrophages originate in the yolk sac, a type of embryonic tissue. Progenitors of macrophages migrate from the yolk sac to various tissues where they settle and renew themselves. Additional macrophages from the bone marrow are only supplied in the case of inflammations or other pathogenic processes. These findings shed new light on these immune cells, which were discovered 150 years ago, but whose origin and development have been poorly understood. The findings were just published in the journal "Nature".

Macrophages (Greek: "big eaters") are cells of the immune system. In tissues, they recognize both foreign invaders (pathogens) and aged cells of the body, which they engulf and digest. Macrophages are specific to different types of tissue. For example, they are called Kupffer cells in the liver, osteoclasts in the bone, alveolar macrophages in the lungs, and microglia in the brain.

These cells are classified as blood cells because they can be cultivated in the lab from specific white blood cells called monocytes. "Therefore, it has been regarded as established that macrophages also arise from stem cells in the bone marrow," says Hans-Reimer Rodewald from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). "Our new results now challenge this textbook view."

The first blood cells are generated in the yolk sac, a special tissue that provides nutrients to the fetus during early embryonic development and later disappears. When that happens the fetal liver first takes over the vital task of providing a continuous supply of new red and white blood cells; later the bone marrow steps in. "We wanted to know whether this also holds true for macrophages that reside in tissue," says Rodewald, "because evidence suggested that these special cells might also have other origins."

The scientists in Rodewald's team labeled progenitor cells with a fluorescent protein in order to identify the point in development when macrophages form and the tissue in which this happens. To dye the cells, they used a special gene switch that had been developed by Katrin Busch, a PhD student in Rodewald's lab. "We could see that the tissue-resident macrophages form very early in the embryonic phase from progenitors in the yolk sac," says Kay Klapproth, one of the two first authors of the study. "This runs counter to what we have believed until now. It shows that macrophages are not supplied from the bone marrow, but renew themselves independently in the tissue where they reside."

"This holds true for macrophages in normal healthy tissue," says Rodewald. "In cases where there is a higher demand for the cells, due to inflammations or a depletion of macrophages, monocytes from the bone marrow appear to be able to provide more tissue macrophages." It is still unclear whether these substitute macrophages carry out the same tasks as the "conventional" macrophages.

The scientists now plan to determine how the original macrophages from the yolk sac are distinguished from “emergency” macrophages called up from the bone marrow. “In certain types of cancer, macrophages might contribute to the spread of tumor cells,” Klapproth says. “In other cases, they are believed to have tumor-inhibiting functions.” At present, it is still unclear whether these contradictory functions might be linked to the different origins of the macrophages. In cancer treatment, it would be desirable to be able to fight “harmful” macrophages and to selectively activate “useful” cells. However, it is not yet possible to distinguish the two cell types from each other. “In the future, it would be exciting if our new findings could be used to distinguish different classes of macrophages based on their origins,” Rodewald says.

Elisa Gomez Perdiguero, Kay Klapproth, Christian Schulz, Katrin Busch, Emanuele Azzoni, Lucile Crozet, Hannah Garner, Celine Trouillet, Marella F. de Bruijn, Frederic Geissmann, Hans-Reimer Rodewald: Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. *Nature* 2014, DOI 10.1038/nature13989

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Contact:

Dr. Stefanie Seltmann
Head of Press and Public Relations
German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2854
F: +49 6221 42 2968
presse@dkfz.de

Dr. Sibylle Kohlstädt
Press and Public Relations
German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2843
F: +49 6221 42 2968
Email: presse@dkfz.de